Trial Profile

A Phase I/II Trial of Ibrutinib (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 02 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary) ; Ibrutinib (Primary)
Indications Mantle-cell lymphoma
Focus Adverse reactions

Most Recent Events

15 Nov 2018 Status changed from active, no longer recruiting to discontinued due to slow accrual.
21 Jul 2017 Planned End Date changed from 1 May 2018 to 1 May 2019.
21 Jul 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com